1-9 of 9
Richard F. Little, MDMPH
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 1 Study of Escalating Doses of Ibrutinib and Temozolomide, Etoposide, Liposomal Doxorubicin, Dexamethasone, Rituximab (TEDDI-R) with Isavuconazole for Relapsed and Refractory Primary CNS Lymphoma

Mark Roschewski, MD, Christopher Melani, MD, Rahul Lakhotia, MD, Stefania Pittaluga, MD PhD, James D. Phelan, PhD, Cody Peer, PhD, Michail S. Lionakis, MD ScD, Lydia L. Chou, CRNP, Matthias Holdhoff, MD PhD, Michael Glantz, MD PhD, Jan Drappatz, MD, Catherine Lai, MD MPH, John A. Butman, MD PhD, Andrea Nicole Lucas, RN, Seth M. Steinberg, PhD, William D. Figg, PhD, Elaine S. Jaffe, MD, S. Percy Ivy, MD, Richard F. Little, MDMPH, Louis M. Staudt, MD PhD, Wyndham H. Wilson, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 12–13.
https://doi.org/10.1182/blood-2020-137637
Published: 2020
Journal Articles

Blast MRD AML-2: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MDR) in Acute Myeloid Leukemia (AML) 2- a Randomized Phase 2 Study of the Venetoclax, Azacitidine, and Pembrolizumab Versus Venetoclax and Azacitidine As First Line Therapy in Older Patients with AML Who Are Ineligible or Who Refuse Intensive Chemotherapy

Amer M. Zeidan, MBBS, MHS, Prajwal Boddu, MD, Brent L Wood, MD PhD, Daniel Zelterman, Richard F. Little, MDMPH, S. Percy Ivy, MD, Anne Caldwell, Beatriz Sanchez-Espiridion, Gheath Alatrash, Elad Sharon, MD MPH, Jerald P. Radich, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 11–12.
https://doi.org/10.1182/blood-2020-139752
Published: 2020
Journal Articles

Blast MRD AML-1 Trial: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia (AML) 1- an Investigator-Initiated, CTEP-Sponsored, Randomized Phase 2 Study of the Anti-PD-1 Antibody Pembrolizumab in Combination with Conventional Intensive Chemotherapy (IC) As Frontline Therapy in Patients with Acute Myeloid Leukemia (AML)

Amer M. Zeidan, MBBS, MHS, Prajwal C Boddu, MBBS, Brent L Wood, MD PhD, Daniel Zelterman, Richard F. Little, MDMPH, S. Percy Ivy, MD, Anne Caldwell, Beatriz Sanchez-Espiridion, Gheath Alatrash, Elad Sharon, MD MPH, Jerald P. Radich, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 15.
https://doi.org/10.1182/blood-2020-139668
Published: 2020
Journal Articles

Risk-Adapted Therapy in Adults with Burkitt Lymphoma: Results of NCI 9177, a Multicenter Prospective Phase II Study of DA-EPOCH-R

Mark Roschewski, MD, Kieron Dunleavy, MD, Jeremy S. Abramson, MD MMSc, Brian K Link, MD, Samir Parekh, MD, Deepa Jagadeesh, MDMPH, Philip Bierman, MD, Ronald T. Mitsuyasu, MD, Ramakrishna Battini, MD, Peter R. Watson, MD, David Peace, MD, Wahid Hanna, MD, Bayard L. Powell, MD, Timothy E. O'Brien, MD, David King, MD, Christopher Melani, MD, Andrea Lucas, RN, Seth M. Steinberg, PhD, Brad S Kahl, MD, Jonathan W. Friedberg, MD, Richard F. Little, MDMPH, Nancy L. Bartlett, MD, Michelle A. Fanale, MD, Ariela Noy, MD, Wyndham H. Wilson, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 188.
https://doi.org/10.1182/blood.V130.Suppl_1.188.188
Published: 2017
Journal Articles

Prospective Study of Acute Myeloid Leukemia (AML) Clinical Epidemiology and Cytogenetic Risk Group in Older Adults in the ECOG-ACRIN E2906 Clinical Trial: The Acute Leukemia Epidemiology, Survival and Endpoints (ALESE) Study

James M. Foran, MD, Yanming Zhang, MD, Michael Heckman, MS, Selina Luger, MD FRCPC, Cassondra Hulshizer, BA, Emily Vargas, MPH, Mark R. Litzow, MD, Jessica K. Altman, MD, Keith Pratz, MD, Ryan Mattison, MD, David F. Claxton, Geoffrey L. Uy, MD, Harry P. Erba, MD PhD, Mohamad A. Cherry, MDMS, Edward R. Broun, MD, Bayard L. Powell, MD, Hillard M Lazarus, MD, Jacob M. Rowe, MD, Elisabeth Paietta, PhD, Richard F. Little, MDMPH, Jen Poynter, PhD, Martin S. Tallman, MD, James R. Cerhan, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2579.
https://doi.org/10.1182/blood.V130.Suppl_1.2579.2579
Published: 2017
Journal Articles

Evaluation of Immune Recovery Following Autologous Hematopoietic Cell Transplantation in HIV-Related Lymphoma: Results of the BMT CTN 0803/AMC 071 Trial

Mat Makowski, PhD, Elshafa Ahmed, DVM, Sarah Schlotter, B.S., Rebecca Pearson, Rhonda Kitzler, MS, Joseph C. Alvarnas, MD, Jennifer Le Rademacher, PhD, Yanli Wang, PhD, Richard F Little, MDMPH, Gorgun Akpek, MD MHS, FACP, Ernesto Ayala, MD, Steven M. Devine, Lawrence D. Kaplan, MD, Ariela Noy, MD PhD, Uday R. Popat, MD, Jack W Hsu, MD, Lawrence E. Morris, MD, Jason Thompson, Mary H Horowitz, MD MS, Adam M. Mendizabal, PhD, Alexandra M. Levine, MD, Amrita Krishnan, MD, Erinn Hade, Craig C Hofmeister, Stephen J. Forman, MD, Willis H. Navarro, MD, Richard F. Ambinder, MD PhD, Gerard Lozanski, MD, Robert A Baiocchi, MD PhD
Journal: Blood
Blood (2016) 128 (22): 1346.
https://doi.org/10.1182/blood.V128.22.1346.1346
Published: 2016
Journal Articles

Veliparib (ABT-888), Bendamustine, and Rituximab (VBR) Is Well Tolerated and Efficacious in Patients with Lymphoma: Final Analysis of a Phase 1b Clinical Trial of VB and a Cohort Expansion of Vbr in Patients with B-Cell Lymphoma

Jacob D Soumerai, MD, Andrew D Zelenetz, MD PhD, Craig H Moskowitz, MD, Anas Younes, MD, Maria Lia Palomba, MD, Paul A Hamlin, Jr., MD, Ariela Noy, MD, Steven M Horwitz, MD, Matthew J. Matasar, MD MS, Alison J Moskowitz, MD, Carol S Portlock, MD, David J Straus, MD, Alice Chen, MD, Richard F Little, MDMPH, Fallon France, Juho Whang, Nishant Mishra, Christine Jarjies, John F Gerecitano, MD PhD
Journal: Blood
Blood (2015) 126 (23): 2691.
https://doi.org/10.1182/blood.V126.23.2691.2691
Published: 2015
Journal Articles

Risk-Adapted Therapy in Adults with Burkitt Lymphoma: Preliminary Report of a Multicenter Prospective Phase II Study of DA-EPOCH-R

Kieron Dunleavy, MD, Ariela Noy, MD, Jeremy S. Abramson, MD, Ann S. LaCasce, MD, Brian K Link, MD, Samir Parekh, MD, Deepa Jagadeesh, MD MPH, Philip J Bierman, MD, Ronald T. Mitsuyasu, MD, Ramakrishna Battini, MD, Peter R Watson, MD, David Peace, MD, Bruce J Averbrook, MD, Harris V. Naina, MD, Joseph W Leach, MD, Wahid T Hanna, MD, Bayard L. Powell, MD, Sunil Nagpal, MD, Mark Roschewski, MD, Andrea N Lucas, RN, Seth M. Steinberg, PhD, Brad S Kahl, MD, Jonathan W. Friedberg, MD MMSc, Richard F Little, MDMPH, Nancy L Bartlett, MD, Michelle A. Fanale, MD, Wyndham H Wilson, MD PhD
Journal: Blood
Blood (2015) 126 (23): 342.
https://doi.org/10.1182/blood.V126.23.342.342
Published: 2015
Journal Articles

Autologous Hematopoietic Stem Cell Transplantation (AHCT) in Patients with Chemotherapy-Sensitive, Relapsed/Refractory (CSRR) Human Immunodeficiency Virus (HIV)-Associated Lymphoma (HAL): Results from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0803)/AIDS Malignancy Consortium (AMC-071) Trial

J Alvarnas, MD, J Le Rademacher, PhD, Y Wang, M.S., Richard F. Little, MDMPH, G Akpek, MD MHS, FACP, E Ayala, MD, S Devine, MD, L Kaplan, MD, A Noy, MD, U Popat, MD, J Thompson, M.S., M H Horowitz, MD MS, A Mendizabal, PhD, W H. Navarro, MD, R Ambinder, MD PhD, Blood and Marrow Transplant Clinical Trials Network (BMT CTN), The AIDS Malignancy Consortium (AMC)
Journal: Blood
Blood (2014) 124 (21): 674.
https://doi.org/10.1182/blood.V124.21.674.674
Published: 2014